Gluten sensitivity among the patients with schizophrenia and the possibility of therapeutic effect of gluten free diet
Not Applicable
- Conditions
- schizophrenia
- Registration Number
- JPRN-UMIN000024074
- Lead Sponsor
- hyogo medical college department of psychiatry
- Brief Summary
There was no significant difference in gluten sensitivity between groups schizophrenia and controls. AG-IgG plasma concentration was significantly higher in patients with schizophrenia than in controls. Treatment-resistant patients in gluten sensitivity were significantly much more than those in non-gluten sensitivity. We found that AG-IgG concentration in treatment-resistant patients is significantly higher than that in non-treatment-resistant patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 280
Inclusion Criteria
Not provided
Exclusion Criteria
patient with remarkable excitement, violent action, self-injurious behavior patient with social behavior patinet who can't provide written informed consent patient who have substance abuse or dependent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of gluten sensitivity is determined by the titer of tissue transglutaminase IgA antibody, the deamidated gliadin peptide IgA antibody, gliadin IgA antibody, gliadin IgGa nti body. The effectiveness of gluten free diet is assessed by PANSS before and two weeks later of taking gluten free diet. Improved patients is assessed at four and eight weeks.
- Secondary Outcome Measures
Name Time Method The comparison between gluten sensitivity group and gluten negative group is performed by PANSS, GAF, SOFAS, QOL-26. The effectiveness of gluten free diet is assessed by CGI-I